Development and Validation of a Simplified Prognostic Score in SCLC.
Chemotherapy
Prognosis
Prognostic score
Serum markers
Small cell lung cancer
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
04
02
2020
accepted:
05
02
2020
entrez:
30
9
2021
pubmed:
12
2
2020
medline:
12
2
2020
Statut:
epublish
Résumé
This study aimed at generating a new simplified prognostic score (SPS) using common clinical and biological variables to discriminate a limited number of subgroups of patients with SCLC differing by their overall survival (OS). The SPS was developed exploring the Montpellier University Hospital retrospective database of 401 patients over a 16-year period. All patients had received etoposide - platinum-based chemotherapy as first-line treatment. The SPS development took into account significant determinants of OS in the Cox model, weighted by their regression β coefficients. Validation of the consequent SPS has been done separately in a combined population of 213 patients accrued from two different published trials (NCT03059667 and NCT00930891). The significant independent determinants of OS included the following: (1) American Joint Committee on Cancer TNM stage IV (hazard ratio [HR]: 2.52; 95% confidence interval [CI]: 1.91-3.33); (2) Eastern Cooperative Oncology Group performance status greater than 1 (HR: 2.27; 95% CI: 1.79-2.87); (3) the presence of liver metastases (HR: 1.66; 95% CI: 1.29-2.15); and (4) neutrophil-to-lymphocyte ratio greater than 4 (HR: 1.39; 95% CI: 1.11-1.92). The SPS generated with these four variables, segregated three groups (good, intermediate, and poor prognosis) with respective median OS of 26.9 months (95% CI: 20.1-38.9), 11.5 months (95% CI: 9.8-13.0), and 6.8 months (95% CI: 5.8-8.3; log-rank The SPS is easy to calculate in real-life practice and efficiently discriminates three populations with different prognoses. This study deserves further validation of this score in patients with SCLC receiving immunochemotherapy.
Identifiants
pubmed: 34589918
doi: 10.1016/j.jtocrr.2020.100016
pii: S2666-3643(20)30016-3
pmc: PMC8474253
doi:
Banques de données
ClinicalTrials.gov
['NCT03059667', 'NCT00930891']
Types de publication
Journal Article
Langues
eng
Pagination
100016Informations de copyright
© 2020 The Authors.
Références
J Cancer. 2019 Jun 2;10(14):3079-3086
pubmed: 31289577
J Thorac Oncol. 2016 Mar;11(3):300-11
pubmed: 26723244
J Clin Oncol. 2007 Sep 1;25(25):3945-51
pubmed: 17761978
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
J Clin Oncol. 2011 Jun 1;29(16):2215-22
pubmed: 21502556
J Thorac Oncol. 2020 Feb;15(2):274-287
pubmed: 31655296
Lung Cancer. 2002 Sep;37(3):271-6
pubmed: 12234695
Int J Cancer. 1987 Feb 15;39(2):146-9
pubmed: 3026969
Clin Cancer Res. 2019 Dec 1;25(23):6958-6966
pubmed: 31506387
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Cancer Discov. 2017 Jun;7(6):620-629
pubmed: 28242752
J Clin Oncol. 2015 May 20;33(15):1660-5
pubmed: 25732163
Ann Oncol. 1997 Jun;8(6):547-53
pubmed: 9261523
Ann Oncol. 2015 May;26(5):908-914
pubmed: 25688059
J Thorac Oncol. 2015 Aug;10(8):1213-20
pubmed: 26200277
J Natl Compr Canc Netw. 2018 Oct;16(10):1171-1182
pubmed: 30323087
Cancer Immunol Res. 2017 May;5(5):417-424
pubmed: 28411193
Eur J Nucl Med Mol Imaging. 2004 Dec;31(12):1614-20
pubmed: 15258700
Cancer Cell. 2017 Feb 13;31(2):286-299
pubmed: 28196596
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Oncotarget. 2016 Aug 16;7(33):53245-53253
pubmed: 27449299
J Thorac Oncol. 2019 May;14(5):903-913
pubmed: 30664989
N Engl J Med. 1993 Dec 16;329(25):1848-52
pubmed: 8247036
Tumour Biol. 2015 Jan;36(1):337-43
pubmed: 25256672
J Thorac Oncol. 2018 Sep;13(9):1338-1348
pubmed: 29902534
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641